Patient-specific mathematical modeling as a precision-medicine approach to evaluating therapeutic gains of a novel chemoprotection treatment in newly diagnosed glioblastoma.

e13041 Background: Glioblastoma (GBM) is the most common and lethal of all brain tumors (median overall survival (OS)14.6 months), yet the incidence is low posing difficulty in creating statistically powered clinical trials, delaying advances in treatment. A patient-specific mathematical model for disease progression coupled with clinical imaging data may provide a tool for quantifying each individual tumor’s response relative to its inherent growth kinetics rather than a universal approach, and, potentially, predicting treatment efficacy. Methods: An exploratory analysis with a patient-specific mathematical model of GBM was used to evaluate therapeutic effect of a novel treatment for newly diagnosed GBM compared to standard care treatment. A cohort of 3 patients from a novel-chemoprotective stem cell gene therapy treatment study (CSCGT) received RT only, followed by dose-intense BCNU and infusion of autologous gene-modified hematopoietic stem cells. Patients then received TMZ combined with O6-benzylguani...